A recent study published in the Journal of Psychopharmacology has offered encouraging preliminary findings for individuals with severe obsessive-compulsive disorder who have not responded to standard ...
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...
Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...
Before lithium became available to treat this potentially devastating illness, bipolar I sufferers experienced repeated ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...
Researchers have identified a second dopamine-driven "clock" in the brain that works alongside the biological 24-hour cycle, ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback